Samsung Life Public Welfare Foundation

Other

Chong Kun Dang Pharmaceutical Corporation

Toolgen Inc.

Young Bin Hong

Jae Young Lee

Jung Min Lee

Seok Joong Kim

Jin Pyo Hong

Seokjoong Kim

Byung-Ok Choi

Dong Woo Song

Byung Ok Choi

Yun Tae Kim

Won Pyo Hong

Sung Chul Jung

So-Youn Woo

Jin-Mo Park

A video-learning monitoring device () includes: a communication unit () for receiving studying video of a student captured by means of a user terminal (); and a score calculation unit () for calculating self-directed learning scores of the student on the basis of the studying video received by means of the communication unit ().

Video-learning monitoring device and method therefor

The present invention relates to an artificially manipulated SC function-controlling factor for SC function control and/or the treatment or alleviation of a disease due to an SC function disorder, and to a use thereof. More specifically, the present invention relates to a system capable of performing artificial SC function control and/or treating or alleviating a disease due to an SC function disorder, the system comprising: an artificially manipulated SC function-controlling factor for SC function control and/or the treatment or alleviation of a disease due to an SC function disorder; and/or a composition for treating or alleviating a disease due to an SC function disorder. In a specific aspect, the present invention relates to an SC function-controlling system by an SC function-controlling factor, such as artificially manipulated PMP22, and/or an expression product thereof.

Artificially engineered SC function control system

An siRNA for specifically targeting a PMP22 mutant gene and a pharmaceutical composition for preventing or treating Charcot Marie Tooth disease, which includes the same, are provided. According to the present invention, it is confirmed that selective suppression of a PMP22 mutant allele by a non-viral delivery system of siRNA may improve demyelinating neuropathic symptoms of CMT in vivo, enhance a motor ability and increase a volume of muscle. Therefore, the siRNA may be used in a useful method for treating various dominantly inherited peripheral neuropathies including CMT.

Pharmaceutical composition for treating Charcot Marie Tooth disease

The present invention relates to a HSP27 mutation (S135F) mediated Charcot-Marie-Tooth disease (CMT) animal model. Particularly, the vector expressing mutant HSP27 protein wherein the 135serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected. The selected mouse was confirmed to display Charcot-Marie-Tooth disease phenotype, so that the animal model was expected to be efficiently used for the evaluation of the effect of Charcot-Marie-Tooth disease treating material candidates.

Animal model of Charcot-Marie-Tooth disease as HSP27 mutant (S135F) carrier

Growing community of inventors

Seoul, South Korea

Young Bin Hong